Biosimilars are back... Or are they?
As blockbuster drugs go off patent, the pharmaceutical industry is scrambling for fresh revenue sources. Follow-on versions of biologics, or "biosimilars," are being pitched as BigPharma's saving grace...
Stories by Khadijah Britton
Biosimilars are back.... Or are they?
As blockbuster drugs go off patent, the pharmaceutical industry is scrambling for fresh revenue sources. Follow-on versions of biologics, or “biosimilars,” are being pitched as BigPharma’s saving grace...
The Data Are In Regarding Satoshi Kanazawa
A Hard Look at Last Week's "Objective Attractiveness" Analysis in Psychology Today If what I say is wrong (because it is illogical or lacks credible scientific evidence), then it is my problem...
